Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bladder Cancer

Free Subscription Articles published in Eur Urol Retrieve available abstracts of 197 articles: HTML format

Single Articles

March 2026
1. CONTIERI R, Lazzeri M, Perdona S, Hurle R, et al
   Re: Hiroshi Kitamura, Taiji Tsukamoto, Yoshiyuki Kakehi, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1
   Eur Urol. 2026 Mar 20:S0302-2838(26)02038-5. doi: 10.1016/j.eururo.2026.
   PubMed    
   
   
   
2. KITAMURA H, Nishiyama H
   Reply to Roberto Contieri, Massimo Lazzeri, Sisto Perdona, and Rodolfo Hurle's Letter to the Editor re: Kitamura, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Nega
   Eur Urol. 2026 Mar 20:S0302-2838(26)02039-7. doi: 10.1016/j.eururo.2026.
   PubMed    
   
   
   February 2026
3. CLARK PE
   Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
   Eur Urol. 2026 Feb 25:S0302-2838(26)01995-0. doi: 10.1016/j.eururo.2026.
   PubMed    
   
   
   
4. NUSBAUM DJ, Li R, Peyton CC, Spiess PE, et al
   Less Is More? How Much Bacillus Calmette-Guerin (BCG) Is Enough for BCG-naive High-risk Non-muscle invasive Bladder Cancer?
   Eur Urol. 2026 Feb 24:S0302-2838(26)02001-4. doi: 10.1016/j.eururo.2026.
   PubMed    
   
   
   
5. LIU P, Chen J, Zhou J
   Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer.
   Eur Urol. 2026 Feb 24:S0302-2838(26)01997-4. doi: 10.1016/j.eururo.2026.
   PubMed    
   
   
   
6. GUPTA S, Li R, Hensley PJ, Daneshmand S, et al
   Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
   Eur Urol. 2026 Feb 21:S0302-2838(26)00059-X. doi: 10.1016/j.eururo.2026.
   PubMed     Abstract available
   
   
   
7. SCILIPOTI P, Zaurito P, Longoni M, Colecchia M, et al
   Corrigendum to "Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials" [Eur. Urol. (2025)].
   Eur Urol. 2026 Feb 17:S0302-2838(26)00063-1. doi: 10.1016/j.eururo.2026.
   PubMed    
   
   
   
8. PICHLER R, Subiela JD, Guerrero-Ramos F
   Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2
   Eur Urol. 2026 Feb 4:S0302-2838(26)00054-0. doi: 10.1016/j.eururo.2026.
   PubMed    
   
   
   
9. GABRIEL PE, Xylinas E
   Re: Ding Ding, Lei Qian, Di Jin, et al. Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study. Eur Urol 2026;89:93-5.
   Eur Urol. 2026 Feb 3:S0302-2838(26)00030-8. doi: 10.1016/j.eururo.2026.
   PubMed    
   
   
   
10. BABJUK M
    Re: Durvalumab in Combination with BCG for BCG-naive, High risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial.
    Eur Urol. 2026 Feb 3:S0302-2838(26)00027-8. doi: 10.1016/j.eururo.2026.
    PubMed    
    
    
    
11. HAYNE D, Zhang AY, Thomas H, Krieger L, et al
    Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette-Guerin-naive Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301).
    Eur Urol. 2026 Feb 2:S0302-2838(26)00015-1. doi: 10.1016/j.eururo.2026.
    PubMed     Abstract available
    
    
    
12. TATEO V, Basile G, Giannatempo P, de Jong JJ, et al
    Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol. 2026 Feb 2:S0302-2838(26)00022-9. doi: 10.1016/j.eururo.2026.
    PubMed     Abstract available
    
    
    
13. MYERS AA, Talwar R, Duan Z, Hensley P, et al
    Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guerin-unresponsive Carcinoma in Situ of the Bladder.
    Eur Urol. 2026;89:151-162.
    PubMed     Abstract available
    
    
    January 2026
14. CABRERA C, Buisan O, Servian P
    Reply to the Harry Herr's Letter to the Editor re: Oscar Buisan, Pol Servian, Sonia Pedreno-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Canc
    Eur Urol. 2026 Jan 23:S0302-2838(26)00018-7. doi: 10.1016/j.eururo.2026.
    PubMed    
    
    
    
15. KITAMURA H, Tsukamoto T, Kakehi Y, Mizusawa J, et al
    Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial.
    Eur Urol. 2026 Jan 21:S0302-2838(26)00014-X. doi: 10.1016/j.eururo.2026.
    PubMed     Abstract available
    
    
    
16. GARMAN TS, Kates MR
    Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2
    Eur Urol. 2026 Jan 19:S0302-2838(26)00016-3. doi: 10.1016/j.eururo.2026.
    PubMed    
    
    
    
17. PICHLER R, Subiela JD, Scilipoti P, Rehder P, et al
    Regional Node-positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings.
    Eur Urol. 2026 Jan 19:S0302-2838(26)00019-9. doi: 10.1016/j.eururo.2026.
    PubMed     Abstract available
    
    
    
18. NAGUMO Y, Kimura T, Ishikawa H, Sekino Y, et al
    Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial.
    Eur Urol. 2026 Jan 17:S0302-2838(25)04872-9. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
19. HERR H
    Re: Oscar Buisan, Pol Servian, Sonia Pedreno-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. Eur Urol.
    Eur Urol. 2026 Jan 12:S0302-2838(25)04897-3. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
20. ROVIELLO G, Vascotto IA, Antonuzzo L
    Re: ctDNA-guided Adjuvant Atezolizumab in Muscle-invasive Bladder Cancer.
    Eur Urol. 2026 Jan 12:S0302-2838(26)00008-4. doi: 10.1016/j.eururo.2026.
    PubMed    
    
    
    December 2025
21. SCILIPOTI P, Zaurito P, Longoni M, Colecchia M, et al
    Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials.
    Eur Urol. 2025 Dec 31:S0302-2838(25)04877-8. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
22. FILHO AM, Briganti A, Jemal A, Bray F, et al
    Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.
    Eur Urol. 2025 Dec 19:S0302-2838(25)04864-X. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
23. PANDOLFO SD, Bukavina L, Autorino R
    Re: ctDNA-guided Adjuvant Atezolizumab in Muscle-invasive Bladder Cancer.
    Eur Urol. 2025 Dec 17:S0302-2838(25)04860-2. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
24. GALLAGHER K, MacLennan S, Bhatt N, Clement K, et al
    RESECT: A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery.
    Eur Urol. 2025 Dec 10:S0302-2838(25)04736-0. doi: 10.1016/j.eururo.2025.09.4174.
    PubMed     Abstract available
    
    
    
25. KHENE ZE, Bensalah K, Roupret M
    Artificial Intelligence for Risk Prediction in Non-muscle-invasive Bladder Cancer: From Complexity to Clinical Clarity.
    Eur Urol. 2025 Dec 3:S0302-2838(25)04831-6. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    November 2025
26. HUANG H, Ma W, Zeng X, Liu B, et al
    Efficacy and Safety of Disitamab Vedotin Combined with Gemcitabine as Neoadjuvant Therapy in Muscle-invasive Bladder Cancer: An Open-label, Multicenter, Single-arm, Phase 2 Trial.
    Eur Urol. 2025 Nov 4:S0302-2838(25)04768-2. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
27. CHU CE, Chen Z, Whiting K, Ostrovnaya I, et al
    Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.
    Eur Urol. 2025;88:472-481.
    PubMed     Abstract available
    
    
    
28. DE WIT R, Vaughn DJ, Fradet Y, Fong L, et al
    Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.
    Eur Urol. 2025;88:462-471.
    PubMed     Abstract available
    
    
    
29. HUSSAIN SA, Catto JWF
    Non-muscle-invasive Bladder Cancer: Many New Options, If You Can Afford Them.
    Eur Urol. 2025 Nov 1:S0302-2838(25)04771-2. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    October 2025
30. MORTEZAVI A
    Re: Sasanlimab plus BCG in BCG-naive, High-risk Non-muscle Invasive Bladder Cancer: The Randomized Phase 3 CREST Trial.
    Eur Urol. 2025 Oct 31:S0302-2838(25)04777-3. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
31. PANEBIANCO V, Briganti A, Efstathiou JA, Galgano SJ, et al
    Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee.
    Eur Urol. 2025 Oct 31:S0302-2838(25)04769-4. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
32. DREYER T, Jensen JB
    Reply to Behzad Jazayeri, Xuefeng Wang, and Roger Li's Letter to the Editor re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive B
    Eur Urol. 2025 Oct 23:S0302-2838(25)04739-6. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
33. JAZAYERI B, Wang X, Li R
    Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur
    Eur Urol. 2025 Oct 16:S0302-2838(25)04729-3. doi: 10.1016/j.eururo.2025.09.4168.
    PubMed    
    
    
    
34. FU MZ, Ghodoussipour S, Packiam VT
    The Future of Bladder Preservation for Muscle-invasive Bladder Cancer.
    Eur Urol. 2025 Oct 16:S0302-2838(25)04734-7. doi: 10.1016/j.eururo.2025.09.4173.
    PubMed    
    
    
    
35. BUISAN O, Servian P, Pedreno-Lopez S, Pages J, et al
    A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial.
    Eur Urol. 2025 Oct 14:S0302-2838(25)00505-6. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
36. DANESHMAND S, Zaucha R, Catto JWF, Tran B, et al
    Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study.
    Eur Urol. 2025 Oct 7:S0302-2838(25)04702-5. doi: 10.1016/j.eururo.2025.09.4152.
    PubMed     Abstract available
    
    
    
37. KWONG JCC, Al-Daqqaq Z, Chelliahpillai Y, Lee S, et al
    Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Can
    Eur Urol. 2025 Oct 7:S0302-2838(25)04688-3. doi: 10.1016/j.eururo.2025.09.4145.
    PubMed     Abstract available
    
    
    
38. MEGHANI K, Yu Y, Frydenlund N, Li EZ, et al
    Genomic and Transcriptomic Profiling of High-risk Bladder Cancer Reveals Diverse Molecular and Microenvironment Ecosystems.
    Eur Urol. 2025 Oct 6:S0302-2838(25)04677-9. doi: 10.1016/j.eururo.2025.09.4138.
    PubMed     Abstract available
    
    
    
39. BELLMUNT J, Powles T, Park SH, Voog E, et al
    Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease.
    Eur Urol. 2025;88:331-338.
    PubMed     Abstract available
    
    
    
40. GALSKY MD, van der Heijden MS, Powles T, Claps M, et al
    Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial.
    Eur Urol. 2025;88:325-330.
    PubMed     Abstract available
    
    
    September 2025
41. SHI Z, Yang S, Yang Y
    Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur
    Eur Urol. 2025 Sep 27:S0302-2838(25)04682-2. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
42. ROVIELLO G, Antonuzzo L
    Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur
    Eur Urol. 2025 Sep 27:S0302-2838(25)04695-0. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
43. DREYER T, Jensen JB
    Reply to Heidi Pharo, Hege Marie Vedeld, Rolf Wahlqvist, and Guro E. Lind's Letter to the Editor re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade
    Eur Urol. 2025 Sep 25:S0302-2838(25)04642-1. doi: 10.1016/j.eururo.2025.09.4129.
    PubMed    
    
    
    
44. PHARO H, Vedeld HM, Wahlqvist R, Lind GE, et al
    Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur
    Eur Urol. 2025 Sep 24:S0302-2838(25)04646-9. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
45. LI X, Wang X, Zhang G
    Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur
    Eur Urol. 2025 Sep 24:S0302-2838(25)04654-8. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
46. DING D, Qian L, Jin D, Zhou X, et al
    Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study.
    Eur Urol. 2025 Sep 19:S0302-2838(25)00493-2. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
47. ZUGMAN M, Carneiro A, Maluf FC
    Challenging the Guidelines: Rethinking Neoadjuvant Therapy for Histologic Subtypes of Bladder Cancer.
    Eur Urol. 2025 Sep 17:S0302-2838(25)00510-X. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
48. HECK MM, Lehmann J, Amiel T, Rubben H, et al
    Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.
    Eur Urol. 2025 Sep 17:S0302-2838(25)00489-0. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    August 2025
49. RAYCHAUDHURI R, Khaki AR, Redman MW, Baker KK, et al
    Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial.
    Eur Urol. 2025 Aug 4:S0302-2838(25)00391-4. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    July 2025
50. GUO Y, Zhang W, Zhang J, Mao S, et al
    Re: Oncolytic Immunotherapy with Nivolumab in Muscle-invasive Bladder Cancer: A Phase 1b Trial.
    Eur Urol. 2025 Jul 28:S0302-2838(25)00406-3. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
51. ANKER JF, Yu M, Galsky MD
    Association Between Circulating Tumor DNA and Clinical Outcomes with Adjuvant Immune Checkpoint Blockade in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Cystectomy.
    Eur Urol. 2025 Jul 1:S0302-2838(25)00342-2. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    June 2025
52. DREYER T, Jensen JB
    Reply to Xin Rui, Xiaoming Xu, and Bo Dai's Letter to the Editor re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Canc
    Eur Urol. 2025 Jun 24:S0302-2838(25)00348-3. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
53. CHANG SS, Launer B, Narayan V, Patil D, et al
    Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association
    Eur Urol. 2025 Jun 12:S0302-2838(25)00338-0. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
54. FU MZ, Ghodoussipour S, Packiam VT
    Re: Bladder-preserving Trimodality Treatment for High-grade T1 Bladder Cancer: Results from Phase II Protocol NRG Oncology/RTOG 0926.
    Eur Urol. 2025 Jun 10:S0302-2838(25)00326-4. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
55. RUI X, Xu X, Dai B
    Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur
    Eur Urol. 2025 Jun 7:S0302-2838(25)00339-2. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    May 2025
56. ST-LAURENT MP, Singh P, McConkey DJ, Lucia MS, et al
    Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2025 May 21:S0302-2838(25)00217-9. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
57. FANKHAUSER CD, Cathomas R
    Re: Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results from the Prospective BladderPath Trial.
    Eur Urol. 2025 May 19:S0302-2838(25)00290-8. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
58. SCHOFIELD E, Catto JWF, Griffin J
    Subtypes and Sequencing in Bladder Cancer: Powering Personalised Treatment or Extraneous Information?
    Eur Urol. 2025 May 16:S0302-2838(25)00277-5. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
59. SUBIELA JD, Scilipoti P, Contieri R, Lobo N, et al
    Management Dilemma for Very High-risk Non-muscle-invasive Bladder Cancer: Real-World Data Challenge the Guideline Recommendation for Upfront Radical Cystectomy.
    Eur Urol. 2025 May 14:S0302-2838(25)00283-0. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
60. WARD DG, Bryan RT
    Should We Incorporate Urinary Tumour DNA Status in Treatment Decisions for Patients with Non-muscle-invasive Bladder Cancer?
    Eur Urol. 2025 May 10:S0302-2838(25)00268-4. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
61. ZAURITO P, Moschini M, Briganti A, Montorsi F, et al
    Re: Douglas M. Dahl, Joseph P. Rodgers, William U. Shipley, et al. Bladder-preserving Trimodality Treatment for High-grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol 2024;42:4095-102.
    Eur Urol. 2025 May 3:S0302-2838(25)00250-7. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    April 2025
62. ALFRED WITJES J
    Follow-up for Non-muscle-invasive Bladder Cancer: Should the Guidelines Be Adapted?
    Eur Urol. 2025 Apr 25:S0302-2838(25)00218-0. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
63. PANEBIANCO V, Briganti A, Efstathiou J, Galgano S, et al
    Reply to Francesco Montorsi, Giuseppe Rosiello, Pietro Scilipoti, Marco Moschini, and Andrea Salonia's Letter to the Editor re: Valeria Panebianco, Alberto Briganti, Jason Efstathiou, et al. The Role of Multiparametric Magnetic Resonance Imaging and t
    Eur Urol. 2025 Apr 24:S0302-2838(25)00199-X. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
64. DREYER T, Brandt S, Fabrin K, Azawi N, et al
    Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial.
    Eur Urol. 2025 Apr 24:S0302-2838(25)00191-5. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
65. GUPTA S, Hensley PJ, Li R, Choudhury A, et al
    Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
    Eur Urol. 2025 Apr 22:S0302-2838(25)00189-7. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
66. GHODOUSSIPOUR S, Bivalacqua T, Bryan RT, Li R, et al
    A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2025 Apr 18:S0302-2838(25)00123-X. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
67. KOSHKIN VS, Danchaivijitr P, Bae WK, Semenov A, et al
    Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.
    Eur Urol. 2025;87:390-395.
    PubMed     Abstract available
    
    
    March 2025
68. VAN DER HEIJDEN AG, Bruins HM, Carrion A, Cathomas R, et al
    European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines.
    Eur Urol. 2025 Mar 17:S0302-2838(25)00138-1. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
69. VAN DOEVEREN T, Aben KKH, van Leeuwen PJ, Boormans JL, et al
    Reply to Alexandra Masson-Lecomte. Bladder Cancer Recurrence Following Management of Upper Tract Urothelial Carcinoma: Balancing Prevention and Iatrogenicity. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.01.004.
    Eur Urol. 2025 Mar 17:S0302-2838(25)00151-4. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
70. MONTORSI F, Rosiello G, Gandaglia G, Salonia A, et al
    Re: Paolo Gontero, Alison Birtle, Otakar Capoun, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update. Eur Urol 2024;86:531-49.
    Eur Urol. 2025 Mar 11:S0302-2838(25)00125-3. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
71. GONTERO P, Soria F
    Reply to Francesco Montorsi, Giuseppe Rosiello, Giorgio Gandaglia, Andrea Salonia and Alberto Briganti's Letter to the Editor re: Paolo Gontero, Alison Birtle, Otakar Capoun, et al. European Association of Urology Guidelines on Non-muscle-invasive Bla
    Eur Urol. 2025 Mar 11:S0302-2838(25)00140-X. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
72. FLAMMIA RS, Leonardo C, Simone G
    Re: Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).
    Eur Urol. 2025 Mar 10:S0302-2838(25)00132-0. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
73. YU M, Goel A, Tura B, Whalley CM, et al
    Towards Epigenetic-based Subtyping of Bladder Cancer: DNA Methylation Predicts Molecular Subtypes of Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2025 Mar 7:S0302-2838(25)00126-5. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    February 2025
74. MONTORSI F, Rosiello G, Scilipoti P, Moschini M, et al
    Re: Valeria Panebianco, Alberto Briganti, Jason Efstathiou, et al. The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the Amer
    Eur Urol. 2025 Feb 27:S0302-2838(25)00120-4. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
75. ECKE TH, Le Calvez-Kelm F, van Poppel H
    Why We Need More Attention on Bladder Cancer: Establishing Policy Recommendations for Health Care Professionals and Politicians.
    Eur Urol. 2025 Feb 19:S0302-2838(25)00095-8. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
76. HURLE R, Bernardini B, Contieri R, Lazzeri M, et al
    Re: Characterizing Psychological Resources and Resilience in Patients with Bladder Cancer: Associations with Frailty and Quality of Life.
    Eur Urol. 2025 Feb 3:S0302-2838(25)00022-3. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
77. LI R, Linscott J, Catto JWF, Daneshmand S, et al
    FGFR Inhibition in Urothelial Carcinoma.
    Eur Urol. 2025;87:110-122.
    PubMed     Abstract available
    
    
    January 2025
78. STENZL A
    The Cost of Bladder Cancer: What Can Be Done?
    Eur Urol. 2025 Jan 28:S0302-2838(25)00017-X. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
79. RAGGI D, Chakrabarti D, Green H, Huddart RA, et al
    Re: Standard or Extended Lymphadenectomy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2025 Jan 27:S0302-2838(25)00020-X. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
80. DAVIS LE, Calaway A, Shoag J
    Re: Robert Huddart, Shaista Hafeez, Clare Griffin, et al. Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomized Controlled Trial. Eur Urol 2025;87:60-70.
    Eur Urol. 2025 Jan 21:S0302-2838(25)00007-7. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
81. MASSON-LECOMTE A
    Bladder Cancer Recurrence Following Management of Upper Tract Urothelial Carcinoma: Balancing Prevention and Iatrogenicity.
    Eur Urol. 2025 Jan 21:S0302-2838(25)00015-6. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
82. FRAGKOULIS C, Bamias A, Gavalas N, Tzannis K, et al
    Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group.
    Eur Urol. 2025 Jan 17:S0302-2838(24)02785-4. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
83. AFFERI L, Cimadamore A, Gallioli A, Pradere B, et al
    Tissue-based Biomarkers Steering Clinical Decisions in Patients with Urothelial Cancer.
    Eur Urol. 2025;87:1-4.
    PubMed     Abstract available
    
    
    December 2024
84. SCILIPOTI P, Moschini M, Li R, Lerner SP, et al
    The Financial Burden of Localized and Metastatic Bladder Cancer.
    Eur Urol. 2024 Dec 26:S0302-2838(24)02744-1. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    October 2024
85. MYERS AA, Kamat AM
    Reply to Christopher Guske, Seyed Behzad Jazayeri, and Roger Li's Letter to the Editor re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Gueri
    Eur Urol. 2024 Oct 15:S0302-2838(24)02642-3. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
86. GUSKE C, Jazayeri SB, Li R
    Re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guerin Have an Effect? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.05.027.
    Eur Urol. 2024 Oct 14:S0302-2838(24)02638-1. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
87. SHARIAT SF
    Navigating the Challenges of BCG-Unresponsive Non-muscle-invasive Bladder Cancer: Insights and Future Directions.
    Eur Urol. 2024 Oct 7:S0302-2838(24)02620-4. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
88. ZHOU W, Zu X, Hu J
    Re: Srikala S. Sridhar, Thomas Powles, Miguel. A. Climent Duran, et al. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance. Eur Ur
    Eur Urol. 2024;86:e96.
    PubMed    
    
    
    
89. NORDENTOFT I, Lindskrog SV, Birkenkamp-Demtroder K, Gonzalez S, et al
    Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
    Eur Urol. 2024;86:301-311.
    PubMed     Abstract available
    
    
    
90. MUNOZ-LOPEZ C, Rathi N, Campbell SC
    Predicting Renal Function following Nephroureterectomy can Impact Timing of Systemic Chemotherapy.
    Eur Urol. 2024;86:378-379.
    PubMed    
    
    
    
91. GAKIS G
    Re: Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer.
    Eur Urol. 2024 Oct 1:S0302-2838(24)02619-8. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    September 2024
92. HUDDART R, Hafeez S, Griffin C, Choudhury A, et al
    Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial.
    Eur Urol. 2024 Sep 24:S0302-2838(24)02596-X. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
93. PANEBIANCO V, Briganti A, Efstathiou J, Galgano S, et al
    The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the American College of Radiology VI-RADS Steering Committee.
    Eur Urol. 2024 Sep 23:S0302-2838(24)02606-X. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
94. CATALANO M, Santoni M, Roviello G
    Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Eur Urol. 2024;86:283.
    PubMed    
    
    
    
95. CHEN DC, AlSaffar H, Graefen H, Perera S, et al
    Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Eur Urol. 2024;86:282-283.
    PubMed    
    
    
    
96. KLUMPER N, Vera-Badillo FE, Eckstein M, Hadaschik B, et al
    Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Eur Urol. 2024;86:280-281.
    PubMed    
    
    
    August 2024
97. BEIJERT IJ, Hagberg O, Gardmark T, Holmberg L, et al
    The Importance of Being Grade 3: A Plea for a Three-tier Hybrid Classification System for Grade in Primary Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Aug 28:S0302-2838(24)02528-4. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
98. PLAGE H, Dressler FF, Fendler A
    Patient-derived Models: A Promising Frontier in Testing the Efficacy of Drugs for Bladder Cancer.
    Eur Urol. 2024 Aug 25:S0302-2838(24)02556-9. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
99. LI R, Hensley PJ, Gupta S, Al-Ahmadie H, et al
    Bladder-sparing Therapy for Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.
    Eur Urol. 2024 Aug 24:S0302-2838(24)02516-8. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
100. COLOMBEL M
     Re: Predicting Non-muscle Invasive Bladder Cancer Outcomes Using Artificial Intelligence: A Systematic Review Using APPRAISE-AI.
     Eur Urol. 2024 Aug 21:S0302-2838(24)02521-1. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
101. BROOKMAN-MAY SD, Kamat AM, May M
     Re: Achieving Benchmarks for National Quality Indicators Reduces Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2024 Aug 19:S0302-2838(24)02553-3. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
102. GONTERO P, Birtle A, Capoun O, Comperat E, et al
     European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update.
     Eur Urol. 2024 Aug 17:S0302-2838(24)02514-4. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
103. MERRILL NM, Kaffenberger SD, Bao L, Vandecan N, et al
     Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response.
     Eur Urol. 2024 Aug 17:S0302-2838(24)02408-4. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
104. COMPERAT E, Wasinger G, Klager J
     Re: Metastasis and Recurrence Patterns in the Molecular Subtypes of Urothelial Bladder Cancer.
     Eur Urol. 2024 Aug 17:S0302-2838(24)02518-1. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
105. DE JONG JJ, Lotan Y, Boormans JL
     Re: EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.
     Eur Urol. 2024 Aug 10:S0302-2838(24)02511-9. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
106. YUEN-CHUN TEOH J, Cheng CH, Tsang CF, Kai-Man Li J, et al
     Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial.
     Eur Urol. 2024;86:103-111.
     PubMed     Abstract available
     
     
     
107. BECCIA V, Pinterpe G, Iacovelli R
     Re: Thomas Powles, Zoe June Assaf, Viraj Degaonkar, et al. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. Eur Urol 2024;85:1
     Eur Urol. 2024;86:e44-e45.
     PubMed    
     
     
     
108. DRAKE MJ, Birder LA
     Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma.
     Eur Urol. 2024;86:183-184.
     PubMed    
     
     
     
109. MANCON S, Ofner H, D'Andrea D
     Re: Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-year Outcomes from a Randomized Controlled Trial.
     Eur Urol. 2024;86:186-187.
     PubMed    
     
     
     July 2024
110. PLIMACK ER, Tangen C, Plets M, Kokate R, et al
     Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.
     Eur Urol. 2024 Jul 12:S0302-2838(24)02453-9. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
111. DEBATIN NF, Bady E, Mandelkow T, Huang Z, et al
     Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer.
     Eur Urol. 2024;86:42-51.
     PubMed     Abstract available
     
     
     June 2024
112. MYERS AA, Tan WS, Grajales V, Hwang H, et al
     Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guerin Have an Effect?
     Eur Urol. 2024 Jun 14:S0302-2838(24)02409-6. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
113. TILGENER C, Bedke J
     Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
     Eur Urol. 2024;85:591-592.
     PubMed    
     
     
     
114. ROSENBERG JE, Mamtani R, Sonpavde GP, Loriot Y, et al
     Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
     Eur Urol. 2024;85:574-585.
     PubMed     Abstract available
     
     
     May 2024
115. BABJUK M
     Can an En Bloc Technique Improve Outcomes of Endoscopic Surgery for Non-muscle-invasive Bladder Cancer?
     Eur Urol. 2024 May 25:S0302-2838(24)02382-0. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
116. ABSOLOM K, Rogers Z, Catto JWF, Bottomley S, et al
     Decision Regret Regarding Treatment Choices 1 Year After a New Diagnosis of Bladder Cancer.
     Eur Urol. 2024 May 11:S0302-2838(24)02346-7. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
117. THALMANN GN
     Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus Open Radical Surgery: All Is in the Eye of the Beholder.
     Eur Urol. 2024;85:431-432.
     PubMed    
     
     
     
118. MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
     Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomised Controlled Trial.
     Eur Urol. 2024;85:422-430.
     PubMed     Abstract available
     
     
     April 2024
119. ST-LAURENT MP, Black PC
     Re: FGFR Inhibition Augments Anti-PD-1 Efficacy in Murine FGFR3-mutant Bladder Cancer by Abrogating Immunosuppression.
     Eur Urol. 2024 Apr 12:S0302-2838(24)02259-0. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
120. BABJUK M
     Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2024 Apr 9:S0302-2838(24)02262-0. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
121. LIEDBERG F, Bobjer J
     Re: Longer is Better for Endoscopic Follow-up of Upper Tract Urothelial Carcinoma After Ureteroscopic Treatment: An Evaluation Spanning 10 Years of Data.
     Eur Urol. 2024;85:392.
     PubMed    
     
     
     
122. LINSCOTT JA, Meeks JJ, Dyrskjot L, Li R, et al
     The Elusive Horizon: Biomarkers in Urothelial Carcinoma.
     Eur Urol. 2024;85:317-319.
     PubMed     Abstract available
     
     
     
123. DAHM P, Ergun O, Sathianathen N
     Re: Pramit Khetrapal, Joanna Kae Ling Wong, Wei Phin Tan, et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Contr
     Eur Urol. 2024;85:e116.
     PubMed    
     
     
     
124. PIRAMIDE F, Turri F, Amparore D, Fallara G, et al
     Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted Radical Cystectomy and Systematic Review of Clinical Outcomes.
     Eur Urol. 2024;85:348-360.
     PubMed     Abstract available
     
     
     
125. COX A, Klumper N, Stein J, Sikic D, et al
     Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.
     Eur Urol. 2024;85:328-332.
     PubMed     Abstract available
     
     
     March 2024
126. DUQUESNE I, de la Taille A
     Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2024 Mar 26:S0302-2838(24)02206-1. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
127. ZHOU Y, D'Andrea VD, Shanmugam SP, Stelter I, et al
     Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer.
     Eur Urol. 2024 Mar 23:S0302-2838(24)02231-0. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
128. ALFRED WITJES J, Bruins HM, Carrion A, Cathomas R, et al
     Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31].
     Eur Urol. 2024 Mar 15:S0302-2838(24)02194-8. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
129. GUPTA S, Necchi A
     LEAP-011 in Urothelial Cancer. Unraveling the Puzzle: Combination or Cohort?
     Eur Urol. 2024;85:239-241.
     PubMed    
     
     
     
130. HUELSTER HL, Gould B, Schiftan EA, Camperlengo L, et al
     Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma.
     Eur Urol. 2024;85:283-292.
     PubMed     Abstract available
     
     
     
131. MATSUBARA N, de Wit R, Balar AV, Siefker-Radtke AO, et al
     Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
     Eur Urol. 2024;85:229-238.
     PubMed     Abstract available
     
     
     
132. HEER R, Tan WS, Gravestock P, Vadiveloo T, et al
     Reply to Arnulf Stenzl, Morgan Roupret, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193-4.
     Eur Urol. 2024;85:309-312.
     PubMed    
     
     
     
133. CAVILLON A, Pouessel D, Houede N, Mathevet F, et al
     Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials.
     Eur Urol. 2024;85:293-300.
     PubMed     Abstract available
     
     
     February 2024
134. VAN DER KWAST TH, Bubendorf L, Cheng L
     International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer: Main Conclusions and Recommendations.
     Eur Urol. 2024 Feb 26:S0302-2838(24)00080-0. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
135. MOSCHINI M, Necchi A, Montorsi F
     Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
     Eur Urol. 2024 Feb 17:S0302-2838(24)00068-X. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
136. SHARIAT SF, Laukhtina E
     Re: Gemcitabine and Cisplatin plus Nivolumab as Organ-sparing Treatment for Muscle-invasive Bladder Cancer: A Phase 2 Trial. Galsky MD, Daneshmand S, Izadmehr S, et al. Nat Med 2023;29:2825-34.
     Eur Urol. 2024 Feb 14:S0302-2838(24)00066-6. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
137. NAOUN N, Loriot Y
     Towards Tailored Adjuvant Therapy in Bladder Urothelial Carcinoma: How Should We Fit Each Size?
     Eur Urol. 2024;85:123-124.
     PubMed    
     
     
     
138. SRIDHAR SS, Powles T, Climent Duran MA, Park SH, et al
     Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
     Eur Urol. 2024;85:154-163.
     PubMed     Abstract available
     
     
     
139. POWLES T, Assaf ZJ, Degaonkar V, Grivas P, et al
     Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
     Eur Urol. 2024;85:114-122.
     PubMed     Abstract available
     
     
     January 2024
140. BINHUMAID FS, Goel A, Gordon NS, Abbotts B, et al
     Circulating Tumour Dna Detection By The Urine-Informed Analysis Of Archival Serum Samples From Muscle-Invasive Bladder Cancer Patients.
     Eur Urol. 2024 Jan 31:S0302-2838(24)00017-4. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
141. KIM SK, Byun YJ, Park SH, Piao XM, et al
     A 23-Gene Prognostic Index Predicts Progression and Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2024 Jan 11:S0302-2838(24)00001-0. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
142. PEDERZOLI F, Riba M, Venegoni C, Marandino L, et al
     Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer.
     Eur Urol. 2024 Jan 5:S0302-2838(23)03341-9. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
143. XIE Q, Shen D
     Re: Bhavan P. Rai, Jose Luis Dominguez Escrig, Luis Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. Eur Urol 2022;82:182-92.
     Eur Urol. 2024;85:e17-e18.
     PubMed    
     
     
     
144. PRASAD RAI B, Violette PD, Imran Omar M
     Reply to Qingpeng Xie and Dianqiu Shen's Letter to the Editor re: Bhavan P. Rai, Jose Luis Dominguez Escrig, Luis Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with H
     Eur Urol. 2024;85:e15-e16.
     PubMed    
     
     
     December 2023
145. YOLMO P, Siemens DR, Koti M
     Predicting Response in TIME and Space: Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
     Eur Urol. 2023 Dec 23:S0302-2838(23)03296-7. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
146. BECKABIR W, Wobker SE, Damrauer JS, Midkiff B, et al
     Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
     Eur Urol. 2023 Dec 12:S0302-2838(23)03261-X. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
147. FENG YN, Xie GY, Xiao L
     Re: Petros Grivas, Se Hoon Park, Eric Voog, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 2023;84:95-108.
     Eur Urol. 2023;84:e145.
     PubMed    
     
     
     
148. PEDERSEN GL, Mogensen K, Rosthoj S, Hermann GG, et al
     Reply to Deng-Xiong Li, De-Chao Feng, and Shi Deng's Letter to the Editor re: Gyrithe Lynghoj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthoj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Blad
     Eur Urol. 2023;84:e154.
     PubMed    
     
     
     
149. LI DX, Feng DC, Deng S
     Re: Gyrithe Lynghoj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthoj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-gui
     Eur Urol. 2023;84:e152-e153.
     PubMed    
     
     
     November 2023
150. KLUMPER N, Eckstein M, Holzel M, Herrmann K, et al
     Re: First-in-Human Study of the Radioligand (68)Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma: Navigating Metastatic Urothelial Cancer with Nectin-4 PET/CT.
     Eur Urol. 2023;84:514-515.
     PubMed    
     
     
     
151. MEEKS JJ, Black PC, Galsky M, Grivas P, et al
     Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection.
     Eur Urol. 2023;84:473-483.
     PubMed     Abstract available
     
     
     
152. MARTINI A, Falagario UG, Russo A, Mertens LS, et al
     Robot-assisted Radical Cystectomy with Orthotopic Neobladder Reconstruction: Techniques and Functional Outcomes in Males.
     Eur Urol. 2023;84:484-490.
     PubMed     Abstract available
     
     
     October 2023
153. WANG Z, Zeng S, Xu C
     Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
     Eur Urol. 2023 Oct 31:S0302-2838(23)03169-X. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
154. HENSLEY PJ, Choudhury A, Khaki AR, Grivas P, et al
     The 2023 European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: A Critical Appraisal.
     Eur Urol. 2023 Oct 31:S0302-2838(23)03208-6. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
155. SEISEN T, Roupret M, Trinh QD, Bellmunt J, et al
     Re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients with Clinically Node-positive Nonmetastatic Bladder Cancer. J
     Eur Urol. 2023 Oct 19:S0302-2838(23)03163-9. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
156. SWINTON M, Hoskin P, Choudhury A
     Reply to Thomas Seisen, Morgan Roupret, Quoc-Dien Trinh, and Joaquim Bellmunt's Letter to the Editor re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alterna
     Eur Urol. 2023 Oct 19:S0302-2838(23)03162-7. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
157. ALFRED WITJES J, Max Bruins H, Carrion A, Cathomas R, et al
     European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.
     Eur Urol. 2023 Oct 17:S0302-2838(23)03073-7. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
158. KULKARNI GS, Wettstein MS
     SWOG S1605: Moving Beyond Systemic Immune Checkpoint Inhibitor Monotherapy in Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2023 Oct 4:S0302-2838(23)03138-X. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
159. KHETRAPAL P, Wong JKL, Tan WP, Rupasinghe T, et al
     Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials.
     Eur Urol. 2023;84:393-405.
     PubMed     Abstract available
     
     
     September 2023
160. FENG M, Matoso A, Epstein G, Fong M, et al
     Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://do
     Eur Urol. 2023 Sep 27:S0302-2838(23)03097-X. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
161. STRANDGAARD T, Nordentoft I, Birkenkamp-Demtroder K, Salminen L, et al
     Field Cancerization Is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer.
     Eur Urol. 2023 Sep 15:S0302-2838(23)03014-2. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
162. INAMURA K
     Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
     Eur Urol. 2023 Sep 9:S0302-2838(23)03085-3. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
163. ZLOTTA AR, Lajkosz K, Efstathiou JA
     Reply to Thomas Seisen, Morgan Roupret, and Pierre Blanchard's Letter to the Editor re: Alexandre R. Zlotta, Leslie K. Ballas, Andrzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institut
     Eur Urol. 2023 Sep 1:S0302-2838(23)03066-X. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     August 2023
164. SEISEN T, Roupret M, Blanchard P
     Re: Alexandre R. Zlotta, Leslie K. Ballas, Anderzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669-81.
     Eur Urol. 2023 Aug 31:S0302-2838(23)03065-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
165. BLACK PC, Tangen CM, Singh P, McConkey DJ, et al
     Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
     Eur Urol. 2023 Aug 16:S0302-2838(23)03019-1. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
166. SUSSMAN J, Konety B, Ahmadi H
     Re: Rakesh Heer, Rebecca Lewis, Thenmalar Vadiveloo, et al. A Randomized Trial of PHOTOdynamic Surgery in Non-muscle-invasive Bladder Cancer. NEJM Evid 2022;1:EVIDoa2200092.
     Eur Urol. 2023 Aug 12:S0302-2838(23)03017-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     July 2023
167. BASILE G, Audenet F, Seisen T, Pradere B, et al
     The Impact of Lineage-specific Transcriptional Factors in Small-cell Bladder Cancer in the Patient Selection Process in Future Clinical Trials.
     Eur Urol. 2023 Jul 25:S0302-2838(23)02969-X. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
168. CIGLIOLA A, Mercinelli C, Patane D, Raggi D, et al
     Re: Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis.
     Eur Urol. 2023 Jul 12:S0302-2838(23)02962-7. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
169. FLAIG TW, Tangen CM, Daneshmand S, Alva AS, et al
     Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
     Eur Urol. 2023 Jul 4:S0302-2838(23)02945-7. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
170. LABAKI C, Saad E, Choueiri TK, Bellmunt J, et al
     Oligometastatic Bladder Cancer: Defining a Novel Entity.
     Eur Urol. 2023 Jul 4:S0302-2838(23)02898-1. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
171. GRIVAS P, Park SH, Voog E, Caserta C, et al
     Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
     Eur Urol. 2023;84:95-108.
     PubMed     Abstract available
     
     
     
172. ROUPRET M, Seisen T, Birtle AJ, Capoun O, et al
     European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
     Eur Urol. 2023;84:49-64.
     PubMed     Abstract available
     
     
     
173. SCHAFER EJ, Jemal A, Wiese D, Sung H, et al
     Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA.
     Eur Urol. 2023;84:117-126.
     PubMed     Abstract available
     
     
     
174. KOTI M, Robert Siemens D
     A Step Closer to Predicting Progression After Bacillus Calmette-Guerin Immunotherapy in High-risk Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2023 Jul 1:S0302-2838(23)02948-2. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     June 2023
175. FENG M, Matoso A, Epstein G, Fong M, et al
     Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer.
     Eur Urol. 2023 Jun 27:S0302-2838(23)02830-0. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
176. GROENEVELD CS, Sanchez-Quiles V, Dufour F, Shi M, et al
     Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
     Eur Urol. 2023 Jun 27:S0302-2838(23)02885-3. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
177. BORREGALES LD, Venkat S, Posada Calderon L, Lewicki P, et al
     A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer.
     Eur Urol. 2023 Jun 21:S0302-2838(23)02900-7. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
178. O'CALLAGHAN M
     Re: Addition of Nintedanib or Placebo to Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Muscle-invasive Bladder Cancer (NEOBLADE): A Double-blind, Randomised, Phase 2 Trial.
     Eur Urol. 2023 Jun 9:S0302-2838(23)02871-3. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
179. MOSCHINI M, Montorsi F
     Re: Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors.
     Eur Urol. 2023;83:582.
     PubMed    
     
     
     
180. LAUKHTINA E, Shariat SF
     Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
     Eur Urol. 2023 Jun 1:S0302-2838(23)02873-7. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     May 2023
181. MAKAROFF LE, Filicevas A, Boldon S, Hensley P, et al
     Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries.
     Eur Urol. 2023 May 24:S0302-2838(23)02801-4. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
182. BAMIAS A, Stenzl A, Brown SL, Albiges L, et al
     Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.
     Eur Urol. 2023 May 20:S0302-2838(23)02810-5. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
183. KOUTROS S, Kiemeney LA, Pal Choudhury P, Milne RL, et al
     Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights.
     Eur Urol. 2023 May 18:S0302-2838(23)02780-X. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
184. JUBBER I, Ong S, Bukavina L, Black PC, et al
     Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors.
     Eur Urol. 2023 May 15:S0302-2838(23)02707-0. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
185. GALSKY MD, Bajorin DF, Witjes JA, Gschwend JE, et al
     Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.
     Eur Urol. 2023;83:432-440.
     PubMed     Abstract available
     
     
     April 2023
186. LENFANT L, Pinar U, Roupret M, Seisen T, et al
     Corrigendum to "First-line Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer: Chimera or "Ne Plus Ultra"?" [Eur Urol 2023].
     Eur Urol. 2023 Apr 17:S0302-2838(23)02714-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
187. MOLINA GE, Schwartz B, Srinivas S, Shah S, et al
     In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity.
     Eur Urol. 2023;83:377-378.
     PubMed    
     
     
     
188. BERGEROT CD, Gupta S
     Time to Rethink Quality of Life Assessment in Patients with Urothelial Cancer in the Current Therapeutic Era?
     Eur Urol. 2023;83:329-330.
     PubMed    
     
     
     
189. GRIVAS P, Kopyltsov E, Su PJ, Parnis FX, et al
     Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
     Eur Urol. 2023;83:320-328.
     PubMed     Abstract available
     
     
     March 2023
190. MOSCHINI M, Salonia A, Briganti A, Montorsi F, et al
     Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
     Eur Urol. 2023 Mar 24:S0302-2838(23)02649-0. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
191. CHENG C, Hu J, Chen J
     Re: Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol. 2023;83:313-7.
     Eur Urol. 2023 Mar 24:S0302-2838(23)02653-2. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
192. CERRATO C, Roupret M, Mir MC
     Results from HIVEC-II for Intermediate-risk Non-muscle-invasive Bladder Cancer: Is This a Dead End for Mitomycin C Hyperthermia?
     Eur Urol. 2023 Mar 23:S0302-2838(23)02643-X. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
193. LENFANT L, Pinar U, Roupret M, Seisen T, et al
     First-line Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer: Chimera or "Ne Plus Ultra"?
     Eur Urol. 2023 Mar 18:S0302-2838(23)02637-4. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
194. GIL-JIMENEZ A, van Dorp J, Contreras-Sanz A, van der Vos K, et al
     Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17].
     Eur Urol. 2023 Mar 10:S0302-2838(23)02641-6. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
195. MAITRE P, Sangar V, Choudhury A
     ADAPT and Improvise: Overcoming Bacillus Calmette-Guerin Unresponsiveness in Non-muscle-invasive Bladder Cancer.
     Eur Urol. 2023 Mar 8:S0302-2838(23)02627-1. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
196. STENZL A, Roupret M, Witjes JA, Gontero P, et al
     High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation.
     Eur Urol. 2023;83:193-194.
     PubMed     Abstract available
     
     
     February 2023
197. SYLVESTER RJ, Rodriguez O, Hernandez V, Turturica D, et al
     Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
     Eur Urol. 2023 Feb 23:S0302-2838(23)02579-4. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum